Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lenzilumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Humanigen
Deal Size : Undisclosed
Deal Type : Agreement
Avid Bioservices Enters Manufacturing Agreement with Humanigen for Lenzilumab
Details : This collaboration enhances commercial production efforts for lenzilumab in advance of potential filings for emergency use authorization (EUA) and subsequent Biologics License Application (BLA) later this year.
Brand Name : Humaneered
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 03, 2021
Lead Product(s) : Lenzilumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Humanigen
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Human monoclonal antiviral antibody
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Recipient : Mapp Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Details : Mapp Biopharmaceutical has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate. Avid and Mapp will immediately commence the initial phas...
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 26, 2020
Lead Product(s) : Human monoclonal antiviral antibody
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Recipient : Mapp Biopharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Terra CoV-2 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Oragenics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under terms of the agreement, Avid will provide Oragenics with analytical method development, process development and drug substance manufacturing services to support development of Oragenics’ novel SARS CoV-2 (COVID-19) spike protein vaccine candidate...
Brand Name : Terra CoV-2
Molecule Type : Vaccine
Upfront Cash : Undisclosed
August 20, 2020
Lead Product(s) : Terra CoV-2 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Oragenics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : IOV-3001
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Iovance Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Iovance Biotherapeutics has selected Avid to provide process development, pilot-batch manufacturing and CGMP manufacturing services to support development of IOV-3001, a novel antibody cytokine engrafted protein.
Brand Name : IOV-3001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
August 06, 2020
Lead Product(s) : IOV-3001
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Iovance Biotherapeutics
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?